Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes
- PMID: 25573878
- DOI: 10.2337/dc14-1186
Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes
Abstract
Objective: Dietary advanced glycation end products (AGEs) and their interactions with the receptor for AGEs (RAGE) may play a role in the pathogenesis of type 1 diabetes. This study set out to assess whether there is any association of circulating concentrations of soluble RAGE (sRAGE), AGEs, and their ratio with the appearance of diabetes-associated autoantibodies in children progressing to clinical diabetes.
Research design and methods: Serum concentrations of sRAGE, N-ε(carboxymethyl)lysine (CML) adducts, and the sRAGE/CML ratio were analyzed in children who progressed to type 1 diabetes. The samples were taken at four time points: before seroconversion, at the time of the first autoantibody-positive sample, at the time of the first sample positive for multiple (>2) autoantibodies, and close to the disease diagnosis. Samples of autoantibody-negative controls matched for age, sex, and HLA-conferred diabetes risk were analyzed at corresponding time points.
Results: The prediabetic children had higher sRAGE concentrations before seroconversion (Pc = 0.03), at the appearance of multiple autoantibodies (Pc = 0.008), and close to diagnosis (Pc = 0.04). Close to diagnosis, the cases had lower CML concentrations than the controls (Pc = 0.004). Prediabetic children had a higher sRAGE/CML ratio than the controls before seroconversion (Pc = 0.008) and at diagnosis (Pc < 0.001).
Conclusions: Prediabetic children have higher concentrations of sRAGE and a higher sRAGE/CML ratio than healthy controls. Circulating sRAGE concentrations seem to decline with the appearance of diabetes-predictive autoantibodies in children progressing to type 1 diabetes. The higher sRAGE/CML ratio in prediabetic children may reflect a higher AGE scavenger capacity.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Similar articles
-
A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetes.Diabetes Metab Res Rev. 2017 May;33(4). doi: 10.1002/dmrr.2872. Epub 2017 Jan 23. Diabetes Metab Res Rev. 2017. PMID: 27883367
-
Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.BJOG. 2012 Nov;119(12):1512-20. doi: 10.1111/j.1471-0528.2012.03463.x. Epub 2012 Aug 20. BJOG. 2012. PMID: 22900949 Free PMC article.
-
Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus.J Pediatr Endocrinol Metab. 2009 Oct;22(10):895-904. doi: 10.1515/jpem.2009.22.10.895. J Pediatr Endocrinol Metab. 2009. PMID: 20020577
-
Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.Curr Drug Targets. 2012 Apr;13(4):526-40. doi: 10.2174/138945012799499758. Curr Drug Targets. 2012. PMID: 22250649 Review.
-
Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?Mol Cell Biochem. 2019 Jan;451(1-2):139-144. doi: 10.1007/s11010-018-3400-2. Epub 2018 Jun 30. Mol Cell Biochem. 2019. PMID: 29961210 Review.
Cited by
-
Type 1 diabetes mellitus prevention: present and future.Nat Rev Endocrinol. 2025 Jun 17. doi: 10.1038/s41574-025-01128-6. Online ahead of print. Nat Rev Endocrinol. 2025. PMID: 40527975 Review.
-
Brain-immune interactions: implication for cognitive impairments in Alzheimer's disease and autoimmune disorders.J Leukoc Biol. 2024 Nov 27;116(6):1269-1290. doi: 10.1093/jleuko/qiae134. J Leukoc Biol. 2024. PMID: 38869088 Free PMC article. Review.
-
Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.Curr Diab Rep. 2016 Oct;16(10):100. doi: 10.1007/s11892-016-0782-y. Curr Diab Rep. 2016. PMID: 27612847 Review.
-
Soluble Receptor for Glycation End-products Concentration Increases Following the Treatment of Severe Diabetic Ketoacidosis.J Clin Res Pediatr Endocrinol. 2020 Jun 3;12(2):160-167. doi: 10.4274/jcrpe.galenos.2019.2019.0076. Epub 2019 Sep 13. J Clin Res Pediatr Endocrinol. 2020. PMID: 31514489 Free PMC article.
-
Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells.Diabetes. 2022 Sep 1;71(9):1994-2008. doi: 10.2337/db22-0177. Diabetes. 2022. PMID: 35713929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials